



March 13, 2026

**BSE Limited**

The Listing Department  
Phiroze Jeejeebhoy Towers  
25<sup>th</sup> Floor, Dalal Street  
Fort, Mumbai 400 001  
Maharashtra, India  
BSE Scrip Code: **544309**

**National Stock Exchange of India Limited**

The Listing Department  
Exchange Plaza, Plot No. C/1, G Block,  
Bandra Kurla Complex  
Bandra (East), Mumbai 400051  
Maharashtra, India  
NSE Symbol: **IKS**

Dear Sir/Ma'am,

**Subject: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Further investment in Inventurus Knowledge Solutions, Inc., a wholly owned subsidiary.**

Pursuant to provisions of Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("**SEBI LODR Regulations**"), we hereby inform that the Board of Directors of Inventurus Knowledge Solutions Limited ("**the Company**") at their meeting held on March 13, 2026 approved a further investment of upto USD 40 Mn in Inventurus Knowledge Solutions, Inc. ("**IKS Inc**"), a wholly owned subsidiary of the Company.

The Meeting of the Board of Directors of the Company commenced at 07:10 p.m. (IST) and concluded at 07:20 p.m. (IST).

The relevant disclosure as required under Regulation 30 of the SEBI LODR Regulations read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/l/3762/2026 dated January 30, 2026 is enclosed as **Annexure -I**.

Kindly take the above-mentioned information on record.

Thanking you,

Yours sincerely  
For **Inventurus Knowledge Solutions Limited**

**Sameer Chavan**  
**Company Secretary and Compliance Officer**  
Membership No.: F7211

Enclosure: As above

**ANNEXURE – I**

**DISCLOSURE UNDER REGULATION 30 OF THE SEBI LODR REGULATIONS READ WITH SEBI MASTER CIRCULAR NO. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 DATED ON JANUARY 30, 2026**

Sr. No.	Particulars	Details								
1.	Name of the target entity, details in brief such as size, turnover etc.	<p>Inventurus Knowledge Solutions Inc. (“IKS Inc.”) is a wholly owned subsidiary of the Company.</p> <p>IKS Inc. is engaged in providing a care enablement platform which comprises of technology-enabled solutions for healthcare providers .</p> <p>Financial Details of IKS Inc:</p> <table border="1" data-bbox="802 835 1507 1075"> <thead> <tr> <th data-bbox="802 835 1214 919">Particulars</th> <th data-bbox="1214 835 1507 919">Amt in INR Mn FY 2024-25</th> </tr> </thead> <tbody> <tr> <td data-bbox="802 919 1214 972">Revenue from Operations</td> <td data-bbox="1214 919 1507 972">6,941.11</td> </tr> <tr> <td data-bbox="802 972 1214 1024">Other Income</td> <td data-bbox="1214 972 1507 1024">55.81</td> </tr> <tr> <td data-bbox="802 1024 1214 1075">Total Income</td> <td data-bbox="1214 1024 1507 1075">6,996.92</td> </tr> </tbody> </table>	Particulars	Amt in INR Mn FY 2024-25	Revenue from Operations	6,941.11	Other Income	55.81	Total Income	6,996.92
Particulars	Amt in INR Mn FY 2024-25									
Revenue from Operations	6,941.11									
Other Income	55.81									
Total Income	6,996.92									
2.	<p>Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired?</p> <p>If yes, nature of interest and details thereof and whether the same is done at "arm's length"</p>	<p>IKS Inc is a wholly owned subsidiary of the Company and therefore related party, and a transaction is on an arm's length basis.</p> <p>None of the Company's promoter / promoter group / group companies have any interest in the said transaction.</p>								
3.	Industry to which the entity being acquired belongs	<p>This is a further investment.</p> <p>Care enablement platform which comprises of technology enabled solutions for healthcare providers.</p>								
4.	Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	Business activities of IKS Inc.								

5	Brief details of any governmental or regulatory approvals required for the acquisition	Not Applicable								
6.	Indicative time period for completion of the acquisition	This is a further investment. On or before May 31, 2026.								
7.	Nature of consideration - whether cash consideration or share swap and details of the same	Cash Consideration								
8.	Cost of acquisition or the price at which the shares are acquired	USD 643.19/- per share for the first tranche of investment of USD 20 Mn.								
9.	Percentage of shareholding / control acquired and / or number of shares acquired.	No. of equity shares to be acquired: Upto 31,096 (This is for an investment amount of USD 20 Mn. The balance 50% will be made in due course).  IKS Inc is a wholly owned subsidiary of the Company and with the aforesaid investment, the shareholding percentage of the Company in IKS Inc remains the same.								
10.	Brief background about the entity acquired in terms of products / line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief);	<p>IKS Inc. was incorporated on September 19, 2006 under the laws of the State of Delaware, USA.</p> <p>IKS Inc. is engaged in the business of assisting U.S. based healthcare service providers deliver better, safer, and more efficient care using a combination of outsourcing and technology. It has its principal place of business in the U.S.</p> <p style="text-align: right;"><i>Amt in INR Mn</i></p> <table border="1"> <thead> <tr> <th>Particulars</th> <th>FY 2024-25</th> <th>FY 2023-24</th> <th>FY 2022-23</th> </tr> </thead> <tbody> <tr> <td>Revenue from operations</td> <td>6,941.11</td> <td>7,027.85</td> <td>6,054.66</td> </tr> </tbody> </table>	Particulars	FY 2024-25	FY 2023-24	FY 2022-23	Revenue from operations	6,941.11	7,027.85	6,054.66
Particulars	FY 2024-25	FY 2023-24	FY 2022-23							
Revenue from operations	6,941.11	7,027.85	6,054.66							